<i>PPM1D</i> Somatic Mutations in Myeloid Neoplasms: Clinical Profile, Clonal Characteristics and Impact of Concurrent Somatic <i>TP53</i> Mutations
Talha Badar(Mayo Clinic in Florida), Mrinal M. Patnaik(Mayo Clinic), Aref Al‐Kali(Mayo Clinic), Abhishek A. Mangaonkar(Mayo Clinic), Ayalew Tefferi(Mayo Clinic), Mohamed A. Kharfan‐Dabaja(Jacksonville College), Rong He(Mayo Clinic), Hemant S. Murthy(University of Florida), Ludovica Marando(Wellcome/MRC Cambridge Stem Cell Institute), James M. Foran(Memorial Sloan Kettering Cancer Center), Liuyan Jiang(Jacksonville College), Yael Kusne(WinnMed), Christy M. Finke(Mayo Clinic), Mark R. Litzow(Mayo Clinic in Arizona), Mobachir El Kettani(Jacksonville College), Yao‐Shan Fan(Jacksonville College), Naseema Gangat(Mayo Clinic in Arizona), David S. Viswanatha(Mayo Clinic), Terra L. Lasho(Mayo Clinic)
Cited by 3
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k